Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by MML Investors Services LLC

MML Investors Services LLC increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 248.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,738 shares of the biopharmaceutical company's stock after purchasing an additional 7,652 shares during the quarter. MML Investors Services LLC's holdings in Alnylam Pharmaceuticals were worth $2,527,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of ALNY. Tidal Investments LLC boosted its stake in shares of Alnylam Pharmaceuticals by 75.1% in the 3rd quarter. Tidal Investments LLC now owns 20,544 shares of the biopharmaceutical company's stock worth $5,650,000 after buying an additional 8,811 shares during the last quarter. American Trust bought a new position in Alnylam Pharmaceuticals in the third quarter valued at about $309,000. Versant Capital Management Inc boosted its position in Alnylam Pharmaceuticals by 77.6% in the fourth quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 83 shares during the last quarter. Everence Capital Management Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at about $593,000. Finally, Nordea Investment Management AB increased its position in shares of Alnylam Pharmaceuticals by 6.7% during the 4th quarter. Nordea Investment Management AB now owns 10,188 shares of the biopharmaceutical company's stock valued at $2,417,000 after purchasing an additional 637 shares during the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CFO Jeffrey V. Poulton sold 967 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $246,749.39. Following the completion of the sale, the chief financial officer now directly owns 32,786 shares in the company, valued at approximately $8,366,003.62. The trade was a 2.86 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total transaction of $362,246.40. Following the sale, the executive vice president now directly owns 12,881 shares in the company, valued at $3,240,344.36. This trade represents a 10.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 7,392 shares of company stock worth $1,875,627. 1.50% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals Trading Up 1.9 %

Alnylam Pharmaceuticals stock traded up $4.80 during mid-day trading on Friday, hitting $259.93. The company's stock had a trading volume of 171,532 shares, compared to its average volume of 882,058. Alnylam Pharmaceuticals, Inc. has a one year low of $144.73 and a one year high of $304.39. The stock has a market cap of $33.81 billion, a PE ratio of -119.62 and a beta of 0.30. The company has a 50 day moving average of $247.93 and a 200-day moving average of $255.50. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The business had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. During the same quarter in the prior year, the firm earned ($0.16) EPS. The firm's revenue for the quarter was up 20.2% compared to the same quarter last year. On average, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. StockNews.com downgraded shares of Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Wednesday. William Blair reiterated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. Needham & Company LLC restated a "buy" rating and issued a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 9th. Scotiabank raised their target price on Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a "sector outperform" rating in a report on Monday, March 31st. Finally, Chardan Capital boosted their price target on Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the company a "buy" rating in a report on Friday. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have assigned a buy rating to the stock. According to MarketBeat, Alnylam Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $316.63.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.